Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Опыт длительного применения интерферонов β в терапии ремиттирующего рассеянного склероза
Опыт длительного применения интерферонов β в терапии ремиттирующего рассеянного склероза
Симанив Т.О., Белкина А.А., Захарова М.Н. Опыт длительного применения интерферонов β в терапии ремиттирующего рассеянного склероза. Consilium Medicum. 2024;26(11):752–758.
DOI: 10.26442/20751753.2024.11.203057
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
DOI: 10.26442/20751753.2024.11.203057
DOI: 10.26442/20751753.2024.11.203057
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
________________________________________________
DOI: 10.26442/20751753.2024.11.203057
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Современные подходы к терапии рассеянного склероза предусматривают достижение контроля над активностью заболевания. Несмотря на многообразие препаратов, которые доказали свою эффективность и вошли в практику в последнее десятилетие, в настоящее время остается актуальным применение препаратов из группы интерферонов β. В статье рассмотрены клинические случаи долгосрочного применения интерферонов β в лечении рассеянного склероза.
Ключевые слова: рассеянный склероз, ПИТРС, интерферон β, клинический случай
Keywords: multiple sclerosis, multiple sclerosis disease modifying drugs, interferon β, clinical case
Ключевые слова: рассеянный склероз, ПИТРС, интерферон β, клинический случай
________________________________________________
Keywords: multiple sclerosis, multiple sclerosis disease modifying drugs, interferon β, clinical case
Полный текст
Список литературы
1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018;378(2):169-80. DOI:10.1056/NEJMra1401483
2. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-86. DOI:10.1212/WNL.0000000000000560
3. Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis – success from bench to bedside. Nat Rev Neurol. 2019;15(1):53-8. DOI:10.1038/s41582-018-0082-z
4. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021;325(8):765-79. DOI:10.1001/jama.2020.26858
5. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655-61. DOI:10.1212/wnl.43.4.655
6. Гусев Е.И., Бойко А.Н. Рассеянный склероз. Научно-практическое руководство. Монография в 2 тт. М.: РООИ Здоровье человека, 2020 [Gusev EI, Boiko AN. Rasseiannyi skleroz. Nauchno-prakticheskoe rukovodstvo. Monografiia v 2 tt. Moscow: ROOI Zdorov'e cheloveka, 2020 (in Russian)].
7. Bierhansl L, Hartung HP, Aktas O, et al. Thinking outside the box: non-canonical targets in multiple sclerosis. Nat Rev Drug Discov. 2022;21(8):578-600.
DOI:10.1038/s41573-022-00477-5
8. Newsome SD, Binns C, Kaunzner UW, et al. No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]. Neurol Ther. 2023;12(6):1909-35. DOI:10.1007/s40120-023-00549-7
9. Журавлева М.В., Давыдовская М.В., Лучинина Е.В., и др. Сравнение клинических преимуществ препаратов второй линии, изменяющих течение рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(8):148‑53 [Zhuravleva MV, Davydovskaya MV, Luchinina EV, et al. Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8):148‑53 (in Russian)]. DOI:10.17116/jnevro2020120081148
10. Yang JH, Rempe T, Whitmire N, et al. Therapeutic Advances in Multiple Sclerosis. Front Neurol. 2022;13:824926. DOI:10.3389/fneur.2022.824926
11. Рассеянный склероз. Клинические рекомендации. 2022. Режим доступа: https://cr.minzdrav.gov.ru/schema/739_1/ Ссылка активна на 10.11.2024 [Rasseiannyi skleroz. Klinicheskie rekomendatsii. 2022. Available at: https://cr.minzdrav.gov.ru/schema/739_1/ Accessed: 10.11.2024 (in Russian)].
12. Laakso SM, Viitala M, Kuusisto H, et al. Multiple sclerosis in Finland 2018-Data from the national register. Acta Neurol Scand. 2019;140(5):303-11. DOI:10.1111/ane.13145
13. Ohlmeier C, Gothe H, Haas J, et al. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data. PLoS One. 2020;15(5):e0231846. DOI:10.1371/journal.pone.0231846
14. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89(2):225-40. DOI:10.1016/j.mayocp.2013.11.002
15. Hellwig K, Thiel S, Haben S, et al. Glatiramer acetate or IFN-β bridging therapy in women with relapsing multiple sclerosis planning a pregnancy. Neurodegener Dis Manag. 2023;13(4):223-34. DOI:10.2217/nmt-2022-0032
16. Jakimovski D, Kolb C, Ramanathan M, et al. Interferon β for Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018;8(11):a032003. DOI:10.1101/cshperspect.a032003
17. Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology. 2010;74(Suppl. 1):S17-24. DOI:10.1212/WNL.0b013e3181c97d99
18. Hojati Z, Kay M, Dehghanian F. Mechanism of Action of Interferon Beta in Treatment of Multiple Sclerosis. In: Multiple Sclerosis. 2016; p. 365-92.
DOI:10.1016/b978-0-12-800763-1.00015-4
19. Giovannoni G, Turner B, Gnanapavan S, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4(4):329-33. DOI:10.1016/j.msard.2015.04.006
20. Ebers GC. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/
remitting multiple sclerosis. Lancet. 1998;352(9139):1498-504. DOI:10.1016/S0140-6736(98)03334-0
21. Zettl UK, Rommer PS, Aktas O, et al. Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation. Expert Rev Clin Immunol. 2023;19(11):1343-59. DOI:10.1080/1744666X.2023.2248391
22. Claflin SB, Tan B, Taylor BV. The long-term effects of disease modifying therapies on disability in people living with multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2019;36:101374. DOI:10.1016/j.msard.2019.08.016
23. Kappos L, Edan G, Freedman MS, et al.; BENEFIT and BENEFIT 15 Study Groups. Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial. J Neurol. 2024;271(7):4599-609. DOI:10.1007/s00415-024-12417-x
24. Попова Е.В., Бойко А.Н., Васильев А.В., и др. Результаты сравнительного клинического исследования российского биоаналога – интерферона-1b (инфибета). Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;112(5):56‑61 [Popova EV, Boiko AN, Vasil'ev AV, et al. Results of a comparative clinical trial of the Russian – interferon-1b bioanalogue (infibeta). S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(5):56‑61 (in Russian)].
25. Попова Е.В., Бойко А.Н., Давыдовская М.В., и др. Опыт применения российского биоаналога интерферона бета-1b (инфибета) в Московском городском центре рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2013;113(10‑2):93‑6 [Popova EV, Boiko AN, Davydovskaya MV, et al. The first experience of the use the Russian interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(10‑2):93‑6 (in Russian)].
26. Коробко Д.С., Барабанова М.А., Бахтиярова К.З., и др. Долгосрочная терапия рассеянного склероза интерфероном бета-1b. Результаты ретроспективного открытого наблюдательного исследования. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2022;122(7‑2):96‑103 [Korobko DS, Barabanova MA, Bakhtiyarova KZ, et al. Long-term treatment for multiple sclerosis with interferon beta-1b. Outcomes of an open, retrospective, observational study. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7‑2):96‑103 (in Russian)]. DOI:10.17116/jnevro202212207296
27. Dobson R, Dassan P, Roberts M, et al. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. Pract Neurol.
2019;19(2):106-14. DOI:10.1136/practneurol-2018-002060
28. Hellwig K, Duarte Caron F, Wicklein EM, et al. Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure. Ther Adv Neurol Disord. 2020;13:1756286420910310. DOI:10.1177/1756286420910310
2. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-86. DOI:10.1212/WNL.0000000000000560
3. Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis – success from bench to bedside. Nat Rev Neurol. 2019;15(1):53-8. DOI:10.1038/s41582-018-0082-z
4. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021;325(8):765-79. DOI:10.1001/jama.2020.26858
5. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655-61. DOI:10.1212/wnl.43.4.655
6. Gusev EI, Boiko AN. Rasseiannyi skleroz. Nauchno-prakticheskoe rukovodstvo. Monografiia v 2 tt. Moscow: ROOI Zdorov'e cheloveka, 2020 (in Russian).
7. Bierhansl L, Hartung HP, Aktas O, et al. Thinking outside the box: non-canonical targets in multiple sclerosis. Nat Rev Drug Discov. 2022;21(8):578-600.
DOI:10.1038/s41573-022-00477-5
8. Newsome SD, Binns C, Kaunzner UW, et al. No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]. Neurol Ther. 2023;12(6):1909-35. DOI:10.1007/s40120-023-00549-7
9. Zhuravleva MV, Davydovskaya MV, Luchinina EV, et al. Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8):148‑53 (in Russian). DOI:10.17116/jnevro2020120081148
10. Yang JH, Rempe T, Whitmire N, et al. Therapeutic Advances in Multiple Sclerosis. Front Neurol. 2022;13:824926. DOI:10.3389/fneur.2022.824926
11. Rasseiannyi skleroz. Klinicheskie rekomendatsii. 2022. Available at: https://cr.minzdrav.gov.ru/schema/739_1/ Accessed: 10.11.2024 (in Russian).
12. Laakso SM, Viitala M, Kuusisto H, et al. Multiple sclerosis in Finland 2018-Data from the national register. Acta Neurol Scand. 2019;140(5):303-11. DOI:10.1111/ane.13145
13. Ohlmeier C, Gothe H, Haas J, et al. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data. PLoS One. 2020;15(5):e0231846. DOI:10.1371/journal.pone.0231846
14. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89(2):225-40. DOI:10.1016/j.mayocp.2013.11.002
15. Hellwig K, Thiel S, Haben S, et al. Glatiramer acetate or IFN-β bridging therapy in women with relapsing multiple sclerosis planning a pregnancy. Neurodegener Dis Manag. 2023;13(4):223-34. DOI:10.2217/nmt-2022-0032
16. Jakimovski D, Kolb C, Ramanathan M, et al. Interferon β for Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018;8(11):a032003. DOI:10.1101/cshperspect.a032003
17. Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology. 2010;74(Suppl. 1):S17-24. DOI:10.1212/WNL.0b013e3181c97d99
18. Hojati Z, Kay M, Dehghanian F. Mechanism of Action of Interferon Beta in Treatment of Multiple Sclerosis. In: Multiple Sclerosis. 2016; p. 365-92.
DOI:10.1016/b978-0-12-800763-1.00015-4
19. Giovannoni G, Turner B, Gnanapavan S, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4(4):329-33. DOI:10.1016/j.msard.2015.04.006
20. Ebers GC. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/
remitting multiple sclerosis. Lancet. 1998;352(9139):1498-504. DOI:10.1016/S0140-6736(98)03334-0
21. Zettl UK, Rommer PS, Aktas O, et al. Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation. Expert Rev Clin Immunol. 2023;19(11):1343-59. DOI:10.1080/1744666X.2023.2248391
22. Claflin SB, Tan B, Taylor BV. The long-term effects of disease modifying therapies on disability in people living with multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2019;36:101374. DOI:10.1016/j.msard.2019.08.016
23. Kappos L, Edan G, Freedman MS, et al.; BENEFIT and BENEFIT 15 Study Groups. Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial. J Neurol. 2024;271(7):4599-609. DOI:10.1007/s00415-024-12417-x
24. Popova EV, Boiko AN, Vasil'ev AV, et al. Results of a comparative clinical trial of the Russian – interferon-1b bioanalogue (infibeta). S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(5):56‑61 (in Russian).
25. Popova EV, Boiko AN, Davydovskaya MV, et al. The first experience of the use the Russian interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(10‑2):93‑6 (in Russian).
26. Korobko DS, Barabanova MA, Bakhtiyarova KZ, et al. Long-term treatment for multiple sclerosis with interferon beta-1b. Outcomes of an open, retrospective, observational study. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7‑2):96‑103 (in Russian). DOI:10.17116/jnevro202212207296
27. Dobson R, Dassan P, Roberts M, et al. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. Pract Neurol.
2019;19(2):106-14. DOI:10.1136/practneurol-2018-002060
28. Hellwig K, Duarte Caron F, Wicklein EM, et al. Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure. Ther Adv Neurol Disord. 2020;13:1756286420910310. DOI:10.1177/1756286420910310
2. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-86. DOI:10.1212/WNL.0000000000000560
3. Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis – success from bench to bedside. Nat Rev Neurol. 2019;15(1):53-8. DOI:10.1038/s41582-018-0082-z
4. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021;325(8):765-79. DOI:10.1001/jama.2020.26858
5. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655-61. DOI:10.1212/wnl.43.4.655
6. Гусев Е.И., Бойко А.Н. Рассеянный склероз. Научно-практическое руководство. Монография в 2 тт. М.: РООИ Здоровье человека, 2020 [Gusev EI, Boiko AN. Rasseiannyi skleroz. Nauchno-prakticheskoe rukovodstvo. Monografiia v 2 tt. Moscow: ROOI Zdorov'e cheloveka, 2020 (in Russian)].
7. Bierhansl L, Hartung HP, Aktas O, et al. Thinking outside the box: non-canonical targets in multiple sclerosis. Nat Rev Drug Discov. 2022;21(8):578-600.
DOI:10.1038/s41573-022-00477-5
8. Newsome SD, Binns C, Kaunzner UW, et al. No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]. Neurol Ther. 2023;12(6):1909-35. DOI:10.1007/s40120-023-00549-7
9. Журавлева М.В., Давыдовская М.В., Лучинина Е.В., и др. Сравнение клинических преимуществ препаратов второй линии, изменяющих течение рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(8):148‑53 [Zhuravleva MV, Davydovskaya MV, Luchinina EV, et al. Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8):148‑53 (in Russian)]. DOI:10.17116/jnevro2020120081148
10. Yang JH, Rempe T, Whitmire N, et al. Therapeutic Advances in Multiple Sclerosis. Front Neurol. 2022;13:824926. DOI:10.3389/fneur.2022.824926
11. Рассеянный склероз. Клинические рекомендации. 2022. Режим доступа: https://cr.minzdrav.gov.ru/schema/739_1/ Ссылка активна на 10.11.2024 [Rasseiannyi skleroz. Klinicheskie rekomendatsii. 2022. Available at: https://cr.minzdrav.gov.ru/schema/739_1/ Accessed: 10.11.2024 (in Russian)].
12. Laakso SM, Viitala M, Kuusisto H, et al. Multiple sclerosis in Finland 2018-Data from the national register. Acta Neurol Scand. 2019;140(5):303-11. DOI:10.1111/ane.13145
13. Ohlmeier C, Gothe H, Haas J, et al. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data. PLoS One. 2020;15(5):e0231846. DOI:10.1371/journal.pone.0231846
14. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89(2):225-40. DOI:10.1016/j.mayocp.2013.11.002
15. Hellwig K, Thiel S, Haben S, et al. Glatiramer acetate or IFN-β bridging therapy in women with relapsing multiple sclerosis planning a pregnancy. Neurodegener Dis Manag. 2023;13(4):223-34. DOI:10.2217/nmt-2022-0032
16. Jakimovski D, Kolb C, Ramanathan M, et al. Interferon β for Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018;8(11):a032003. DOI:10.1101/cshperspect.a032003
17. Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology. 2010;74(Suppl. 1):S17-24. DOI:10.1212/WNL.0b013e3181c97d99
18. Hojati Z, Kay M, Dehghanian F. Mechanism of Action of Interferon Beta in Treatment of Multiple Sclerosis. In: Multiple Sclerosis. 2016; p. 365-92.
DOI:10.1016/b978-0-12-800763-1.00015-4
19. Giovannoni G, Turner B, Gnanapavan S, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4(4):329-33. DOI:10.1016/j.msard.2015.04.006
20. Ebers GC. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/
remitting multiple sclerosis. Lancet. 1998;352(9139):1498-504. DOI:10.1016/S0140-6736(98)03334-0
21. Zettl UK, Rommer PS, Aktas O, et al. Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation. Expert Rev Clin Immunol. 2023;19(11):1343-59. DOI:10.1080/1744666X.2023.2248391
22. Claflin SB, Tan B, Taylor BV. The long-term effects of disease modifying therapies on disability in people living with multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2019;36:101374. DOI:10.1016/j.msard.2019.08.016
23. Kappos L, Edan G, Freedman MS, et al.; BENEFIT and BENEFIT 15 Study Groups. Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial. J Neurol. 2024;271(7):4599-609. DOI:10.1007/s00415-024-12417-x
24. Попова Е.В., Бойко А.Н., Васильев А.В., и др. Результаты сравнительного клинического исследования российского биоаналога – интерферона-1b (инфибета). Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;112(5):56‑61 [Popova EV, Boiko AN, Vasil'ev AV, et al. Results of a comparative clinical trial of the Russian – interferon-1b bioanalogue (infibeta). S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(5):56‑61 (in Russian)].
25. Попова Е.В., Бойко А.Н., Давыдовская М.В., и др. Опыт применения российского биоаналога интерферона бета-1b (инфибета) в Московском городском центре рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2013;113(10‑2):93‑6 [Popova EV, Boiko AN, Davydovskaya MV, et al. The first experience of the use the Russian interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(10‑2):93‑6 (in Russian)].
26. Коробко Д.С., Барабанова М.А., Бахтиярова К.З., и др. Долгосрочная терапия рассеянного склероза интерфероном бета-1b. Результаты ретроспективного открытого наблюдательного исследования. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2022;122(7‑2):96‑103 [Korobko DS, Barabanova MA, Bakhtiyarova KZ, et al. Long-term treatment for multiple sclerosis with interferon beta-1b. Outcomes of an open, retrospective, observational study. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7‑2):96‑103 (in Russian)]. DOI:10.17116/jnevro202212207296
27. Dobson R, Dassan P, Roberts M, et al. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. Pract Neurol.
2019;19(2):106-14. DOI:10.1136/practneurol-2018-002060
28. Hellwig K, Duarte Caron F, Wicklein EM, et al. Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure. Ther Adv Neurol Disord. 2020;13:1756286420910310. DOI:10.1177/1756286420910310
________________________________________________
2. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-86. DOI:10.1212/WNL.0000000000000560
3. Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis – success from bench to bedside. Nat Rev Neurol. 2019;15(1):53-8. DOI:10.1038/s41582-018-0082-z
4. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021;325(8):765-79. DOI:10.1001/jama.2020.26858
5. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655-61. DOI:10.1212/wnl.43.4.655
6. Gusev EI, Boiko AN. Rasseiannyi skleroz. Nauchno-prakticheskoe rukovodstvo. Monografiia v 2 tt. Moscow: ROOI Zdorov'e cheloveka, 2020 (in Russian).
7. Bierhansl L, Hartung HP, Aktas O, et al. Thinking outside the box: non-canonical targets in multiple sclerosis. Nat Rev Drug Discov. 2022;21(8):578-600.
DOI:10.1038/s41573-022-00477-5
8. Newsome SD, Binns C, Kaunzner UW, et al. No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]. Neurol Ther. 2023;12(6):1909-35. DOI:10.1007/s40120-023-00549-7
9. Zhuravleva MV, Davydovskaya MV, Luchinina EV, et al. Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8):148‑53 (in Russian). DOI:10.17116/jnevro2020120081148
10. Yang JH, Rempe T, Whitmire N, et al. Therapeutic Advances in Multiple Sclerosis. Front Neurol. 2022;13:824926. DOI:10.3389/fneur.2022.824926
11. Rasseiannyi skleroz. Klinicheskie rekomendatsii. 2022. Available at: https://cr.minzdrav.gov.ru/schema/739_1/ Accessed: 10.11.2024 (in Russian).
12. Laakso SM, Viitala M, Kuusisto H, et al. Multiple sclerosis in Finland 2018-Data from the national register. Acta Neurol Scand. 2019;140(5):303-11. DOI:10.1111/ane.13145
13. Ohlmeier C, Gothe H, Haas J, et al. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data. PLoS One. 2020;15(5):e0231846. DOI:10.1371/journal.pone.0231846
14. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89(2):225-40. DOI:10.1016/j.mayocp.2013.11.002
15. Hellwig K, Thiel S, Haben S, et al. Glatiramer acetate or IFN-β bridging therapy in women with relapsing multiple sclerosis planning a pregnancy. Neurodegener Dis Manag. 2023;13(4):223-34. DOI:10.2217/nmt-2022-0032
16. Jakimovski D, Kolb C, Ramanathan M, et al. Interferon β for Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018;8(11):a032003. DOI:10.1101/cshperspect.a032003
17. Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology. 2010;74(Suppl. 1):S17-24. DOI:10.1212/WNL.0b013e3181c97d99
18. Hojati Z, Kay M, Dehghanian F. Mechanism of Action of Interferon Beta in Treatment of Multiple Sclerosis. In: Multiple Sclerosis. 2016; p. 365-92.
DOI:10.1016/b978-0-12-800763-1.00015-4
19. Giovannoni G, Turner B, Gnanapavan S, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4(4):329-33. DOI:10.1016/j.msard.2015.04.006
20. Ebers GC. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/
remitting multiple sclerosis. Lancet. 1998;352(9139):1498-504. DOI:10.1016/S0140-6736(98)03334-0
21. Zettl UK, Rommer PS, Aktas O, et al. Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation. Expert Rev Clin Immunol. 2023;19(11):1343-59. DOI:10.1080/1744666X.2023.2248391
22. Claflin SB, Tan B, Taylor BV. The long-term effects of disease modifying therapies on disability in people living with multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2019;36:101374. DOI:10.1016/j.msard.2019.08.016
23. Kappos L, Edan G, Freedman MS, et al.; BENEFIT and BENEFIT 15 Study Groups. Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial. J Neurol. 2024;271(7):4599-609. DOI:10.1007/s00415-024-12417-x
24. Popova EV, Boiko AN, Vasil'ev AV, et al. Results of a comparative clinical trial of the Russian – interferon-1b bioanalogue (infibeta). S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(5):56‑61 (in Russian).
25. Popova EV, Boiko AN, Davydovskaya MV, et al. The first experience of the use the Russian interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(10‑2):93‑6 (in Russian).
26. Korobko DS, Barabanova MA, Bakhtiyarova KZ, et al. Long-term treatment for multiple sclerosis with interferon beta-1b. Outcomes of an open, retrospective, observational study. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7‑2):96‑103 (in Russian). DOI:10.17116/jnevro202212207296
27. Dobson R, Dassan P, Roberts M, et al. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. Pract Neurol.
2019;19(2):106-14. DOI:10.1136/practneurol-2018-002060
28. Hellwig K, Duarte Caron F, Wicklein EM, et al. Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure. Ther Adv Neurol Disord. 2020;13:1756286420910310. DOI:10.1177/1756286420910310
Авторы
Т.О. Симанив*, А.А. Белкина, М.Н. Захарова
ФГБНУ «Научный центр неврологии», Москва, Россия
*tarassimaniv@gmail.com
Research Center of Neurology, Moscow, Russia
*tarassimaniv@gmail.com
ФГБНУ «Научный центр неврологии», Москва, Россия
*tarassimaniv@gmail.com
________________________________________________
Research Center of Neurology, Moscow, Russia
*tarassimaniv@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.